Le Lézard
Classified in: Health, Covid-19 virus
Subject: TDS

FDAnews Announces -- Meeting Global Unique Device Identification Requirements: Regulation, Compliance, and Best Practices Webinar July 29, 2020


FALLS CHURCH, Va., July 15, 2020 /PRNewswire-PRWeb/ -- Searching for the best way to fulfill the competing needs of various device identification requirements? Looking for the most efficient way to appropriately identify a product in different global markets?

The task of meeting unique device identification (UDI) guidelines can be complicated. Requirements around the world are evolving and despite efforts by the Global Harmonization Task Force and International Medical Device Regulator Forum to integrate global expectations, they are evolving in different ways in different places.

Even now, when the deadline for final implementation of Class I products is quickly approaching in the United States and UDI timelines in the EU remain unchanged due to COVID-19, regulatory bodies in other countries are starting to implement their own new programs.

UDI expert Jay Crowley will share ways to manage multiple regulatory bodies, best practices around establishing and maintaining robust and effective global UDI processes, possible responses to distinct local UDI concerns and how to submit identification product data to various stakeholders:

The Evolution of Universal Device Identification Guidelines:

Intertwining Regulatory, Commercial and Patient-Safety Information:

Initial Development, Maintenance and Reuse of Information:

UDI Best Practices:

Finding the best way to meet shifting global identification obligations is a complicated balancing act. Learn how to navigate the process and discover the most effective, practical solutions to international UDI concerns.

Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.

Webinar Details:
Meeting Global Unique Device Identification Requirements:
Regulation, Compliance, and Best Practices
An FDAnews Webinar
Wednesday, July 29, 2020, 1:30 p.m.-3:00 p.m. EDT
https://www.fdanews.com/udirequirements

Tuition:
$287 per site

Easy Ways to Register:
Online: https://www.fdanews.com/udirequirements
By phone: 888.838.5578 or 703.538.7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations

 

SOURCE FDAnews


These press releases may also interest you

at 18:00
NeoTract, a wholly owned subsidiary of Teleflex Incorporated focused on addressing unmet needs in the field of urology, today announced that Robert Waguespack, M.D., Robert L. Waguespack, M.D. in Bakersfield, CA, has been designated as a UroLift®...

at 17:56
CHAMPS Group Purchasing (GPO), in collaboration with four Cleveland-area agencies and organizations, is pleased to announce today its "Give Back With CHAMPS GPO" campaign in support of Northeast Ohio nonprofits. As part of the initiative, CHAMPS GPO...

at 17:45
The "Esophagoscopes and Gastroscopes (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering. This market model is built to visualize quantitative market...

at 17:40
Ligand Pharmaceuticals Incorporated and Pfenex Inc. today announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12.00 per share in cash or $438 million in equity value on a fully diluted basis....

at 17:29
San Antonio-area law firms Wyatt Law Firm, PLLC, and Carabin Shaw are partnering to assist the South Texas Blood & Tissue Center's (STBTC) efforts to collect convalescent plasma for COVID-19 patients. The two firms will provide $50,000.00 each ?...

at 17:25
The U.S. Food and Drug Administration (FDA) today continued to take action in the ongoing response to the COVID-19 pandemic: As part of the FDA's effort to protect consumers, the agency issued a warning letter to one firm for selling unapproved...



News published on 15 july 2020 at 00:00 and distributed by: